Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Pregnancy is not an indication
for discontinuing or delaying combined antiretroviral therapy (CART) in women
with human immunodeficiency virus (HIV) infection, but concerns remain about
potential adverse effects for the infant.1,2 Prior
small case series have suggested an increased risk for hemangioma.3,4 We assessed the risk of hemangioma
and other congenital malformations in a somewhat larger cohort of infants
exposed to CART in utero, as well as in a comparison cohort.
De Santis M, Cavaliere AF, Caruso A, Villa P, Tamburrini E, Cauda R, Fundaro C, Genovese O. Hemangiomas and Other Congenital Malformations in Infants Exposed to Antiretroviral Therapy In Utero. JAMA. 2004;291(3):305. doi:10.1001/jama.291.3.305